American Society of Hematology

As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs that efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.

Content to be used in accordance with local CPO guidelines

List of Presentations

Ruxolitinib Plus Nivolumab in Patients With R/R Hodgkin Lymphoma After Failure of Check-Point Inhibitors: Preliminary Report on Safety and Efficacy

Bachanova V

  • Presentation # 230 – Oral*
    December 11, 2021 | 02:15 PM EST

A Real-World Evaluation of the Association Between Elevated Blood Counts and Thrombotic Events in Polycythemia Vera (Analysis of Data From the REVEAL Study)

Gerds AT

  • Presentation # 239 – Oral*
    December 11, 2021 | 03:00 PM EST

A Phase II Study of Ruxolitinib Pre-, During- and Post-Hematopoietic Cell Transplantation for Patients With Primary or Secondary Myelofibrosis

Hobbs G

  • Presentation # 169 – Oral*
    December 11, 2021 | 12:00 PM EST

Validation of Amphiregulin as a Monitoring Biomarker During Treatment of Life-Threatening Acute GVHD: A Secondary Analysis of 2 Prospective Clinical Trials

Pratta M

  • Presentation # 259 – Oral*
    December 11, 2021 | 02:00 PM EST

Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients With Relapsed or Refractory Multiple Myeloma

Berenson JR

  • Presentation # 2727 – Poster*
    December 12, 2021 | 06:00 PM EST

Novel Combination Therapy of Venetoclax and Ruxolitinib in the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia

Borate U

  • Presentation # 2333 – Poster*
    December 12, 2021 | 06:00 PM EST

Disability Associated With Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

Hamilton BK

  • Presentation # 4060 – Poster*
    December 13, 2021 | 06:00 PM EST

Characteristics of High-Risk Polycythemia Vera Patients With Suboptimal Response to First-Line Therapy Who Switched to Ruxolitinib Vs Those Who Did Not Switch: Findings From PV-SWITCH, a Multinational, Retrospective Chart Review Study

Koschmieder S

  • Presentation # 3646 – Poster
    December 13, 2021 | 06:00 PM EST

This presentation will be available once the congress embargo lifts

Patient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT)

Lee SJ

  • Presentation # 3909 – Poster
    December 13, 2021 | 06:00 PM EST

This presentation will be available once the congress embargo lifts

Community Versus Academic Practice in Essential Thrombocythemia and Myelofibrosis: Differences in Clinical Characteristics, Diagnosis, Treatment Patterns, and Symptom Burden (Analysis of Data From the MOST Study)

Lyons R

  • Presentation # 1497 – Poster*
    December 11, 2021 | 05:30 PM EST

ADORE: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients With Myelofibrosis

Ross DM

  • Presentation # 1489 – Poster
    December 11, 2021 | 05:30 PM EST

This presentation will be available once the congress embargo lifts

Second Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CML)

Sweet K

  • Presentation # 2555 – Poster*
    December 12, 2021 | 06:00 PM EST

Does Early Intervention in Myelofibrosis Impact Outcomes? A Pooled Analysis of the COMFORT I and II Studies

Verstovsek S

  • Presentation # 1505 – Poster*
    December 11, 2021 | 05:30 PM EST

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Add-On Parsaclisib in Patients With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib

Yacoub A

  • Presentation # 1502 – Poster*
    December 11, 2021 | 05:30 PM EST

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients With JAK- and PI3K-Inhibitor Treatment–Naive Myelofibrosis

Yacoub A

  • Presentation # 2579 – Poster*
    December 12, 2021 | 06:00 PM EST

Subgroup Analysis From a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination With Ruxolitinib in Patients With Myelofibrosis (MF)

Yacoub A

  • Presentation # 3647 – Poster*
    December 13, 2021 | 06:00 PM EST

*For non-US physicians only. US physicians should visit Incyte’s booth here

View list of select presentations for this compound